announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response ...

The new data from the open-label extension period showed that at 100 weeks, 64 and 57 percent of patients initially treated with SKYRIZI achieved ACR20 response in KEEPsAKE 1 and 2, respectively.

Patients who achieved endoscopic response or remission after induction ... Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations ...

lost response, or were intolerant to either conventional or biologic therapy. The recommended treatment regime with AbbVie’s Skyrizi involves an intravenous induction dose of 1200 mg ...

Skyrizi was also demonstrated to be superior to Stelara across all secondary endpoints. These included the percentage of patients achieving Crohn’s Disease Activity Index of less than 150 at week 48, ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...